{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:35:46Z","timestamp":1790908546006,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,6]],"date-time":"2027-02-06T00:00:00Z","timestamp":1801872000000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T06:15:32Z","timestamp":1759558532000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia\u2014How to Define the Treatment Value?"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi G.","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Stenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clml.2025.10.001_bib0001","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.10.001_bib0002","series-title":"Harrison's Principles of Internal Medicine, 21e","author":"Kantarjian","year":"2022"},{"issue":"9","key":"10.1016\/j.clml.2025.10.001_bib0003","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood.2024026311","article-title":"Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"145","author":"Guilhot","year":"2025","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.10.001_bib0004","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2025.10.001_bib0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus Imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2025.10.001_bib0006","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.10.001_bib0007","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.10.001_bib0008","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.10.001_bib0009","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.001_bib0010","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1182\/blood-2023-182981","article-title":"The use of 2 nd generation TKIs As first line therapy does not prevent CML related deaths: results of an Italian CML campus prospective study in 1277 patients treated first line with Imatinib or 2 nd generation TKIs","volume":"142","author":"Giai","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.10.001_bib0011","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.10.001_bib0012","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1016\/S2352-3026(23)00164-3","article-title":"Revisiting six established practices in the treatment of chronic myeloid leukaemia","volume":"10","author":"Kantarjian","year":"2023","journal-title":"Lancet Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.10.001_bib0013","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.10.001_bib0014","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.10.001_bib0015","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.clml.2024.08.009","article-title":"Deep molecular response rate in chronic phase chronic myeloid leukemia: Eligibility to discontinuation related to time to response and different frontline TKI in the experience of the gimema labnet CML national network","volume":"25","author":"Breccia","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2025.10.001_bib0016","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41375-024-02229-3","article-title":"Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?","volume":"38","author":"Kantarjian","year":"2024","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.clml.2025.10.001_bib0017","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.10.001_bib0018","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V112.11.334.334","volume":"112","author":"Goldman","year":"2008","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.001_bib0019","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1182\/blood-2024-208569","article-title":"Early predictors of treatment-free remission in chronic myeloid leukemia","volume":"144","author":"Farhat","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2025.10.001_bib0020","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2025.10.001_bib0021","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.10.001_bib0022","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.10.001_bib0023","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Can J"},{"issue":"4","key":"10.1016\/j.clml.2025.10.001_bib0024","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in ``good-risk'' chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.10.001_bib0025","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new Prognostic score for survival of patients with chronic myeloid leukemia treated with Interferon Alfa writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"JNCI: J Nat Can Institute"},{"issue":"8","key":"10.1016\/j.clml.2025.10.001_bib0026","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/s41375-020-0931-9","article-title":"The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia","volume":"34","author":"Pfirrmann","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2025.10.001_bib0027","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","article-title":"Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study","volume":"6","author":"Shih","year":"2019","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.clml.2025.10.001_bib0028","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/cncr.35038","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy\u2014The Surveillance, Epidemiology, and End Results database, 2000\u20132019","volume":"129","author":"Sasaki","year":"2023","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.clml.2025.10.001_bib0029","first-page":"7","article-title":"Why drugs cost too much and how prices can be brought down","volume":"39","author":"Kantarjian","year":"2013","journal-title":"The Cancer Letter"},{"issue":"4","key":"10.1016\/j.clml.2025.10.001_bib0030","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.mayocp.2015.01.014","article-title":"Why are cancer drugs so expensive in the United States, and what are the solutions?","volume":"90","author":"Kantarjian","year":"2015","journal-title":"Mayo Clinic Proc"},{"issue":"4","key":"10.1016\/j.clml.2025.10.001_bib0031","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1200\/JOP.2013.001351","article-title":"High cancer drug prices in the United States: reasons and proposed solutions","volume":"10","author":"Kantarjian","year":"2014","journal-title":"J Oncol Pract"},{"issue":"12","key":"10.1016\/j.clml.2025.10.001_bib0032","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/ajh.25284","article-title":"American (cancer) patients first\u201d plan to reduce drug prices\u2014a critical assessment","volume":"93","author":"Kantarjian","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.10.001_bib0033","series-title":"Health Care Costs: What\u2019s the Problem?","author":"Grover","year":"2022"},{"key":"10.1016\/j.clml.2025.10.001_bib0034","unstructured":"Eurostat. Government expenditure on health. 2025. https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Government_expenditure_on_health, Accessed 6 October, 2025."},{"issue":"22","key":"10.1016\/j.clml.2025.10.001_bib0035","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood"},{"issue":"aug07 1","key":"10.1016\/j.clml.2025.10.001_bib0036","doi-asserted-by":"crossref","first-page":"e4348","DOI":"10.1136\/bmj.e4348","article-title":"Pharmaceutical research and development: what do we get for all that money?","volume":"345","author":"Light","year":"2012","journal-title":"Bmj"},{"key":"10.1016\/j.clml.2025.10.001_bib0037","series-title":"Magic cancer bullet: how a tiny orange pill is rewriting medical history","author":"Vasella","year":"2003"},{"issue":"1","key":"10.1016\/j.clml.2025.10.001_bib0038","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7116","article-title":"Navigating the management of chronic phase CML in the era of generic BCR::ABL1 tyrosine kinase inhibitors","volume":"22","author":"Haddad","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.clml.2025.10.001_bib0039","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.10.001_bib0040","article-title":"CostPlus and implications for generic imatinib","volume":"13","author":"Jenei","year":"2022","journal-title":"Lancet Region Health"},{"issue":"11","key":"10.1016\/j.clml.2025.10.001_bib0041","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood-2015-11-680058","article-title":"Strategies that delay or prevent the timely availability of affordable generic drugs in the United States","volume":"127","author":"Jones","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.10.001_bib0042","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/cncr.30545","article-title":"High cancer drug prices 4 years later-progress and prospects","volume":"123","author":"Kantarjian","year":"2017","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clml.2025.10.001_bib0043","doi-asserted-by":"crossref","first-page":"e854","DOI":"10.1016\/S2352-3026(22)00246-0","article-title":"The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA","volume":"9","author":"Kantarjian","year":"2022","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.clml.2025.10.001_bib0044","first-page":"4","article-title":"The Trump administration \u201cAmerican patients first\u201d plan to reduce drug prices\u2014are American cancer patients first?","volume":"44","author":"Kantarjian","year":"2018","journal-title":"Can Letter"},{"issue":"6","key":"10.1016\/j.clml.2025.10.001_bib0045","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JOP.2016.019737","article-title":"Journey of generic Imatinib: a case study in oncology drug pricing","volume":"13","author":"Chen","year":"2017","journal-title":"J Oncol Pract"},{"issue":"6","key":"10.1016\/j.clml.2025.10.001_bib0046","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamaoncol.2015.1024","article-title":"Having \u201cskin in the game\u201d and allowing cross-border importation of drugs to lower high prices of cancer drugs","volume":"1","author":"Kantarjian","year":"2015","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.10.001_bib0047","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.mayocp.2015.06.001","article-title":"In support of a patient-driven initiative and petition to lower the high price of cancer drugs","volume":"90","author":"Tefferi","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.clml.2025.10.001_bib0048","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.mayocp.2012.07.007","article-title":"The high cost of cancer drugs and what we can do about it","volume":"87","author":"Siddiqui","year":"2012","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.clml.2025.10.001_bib0049","series-title":"The savings from an efficient medicare prescription drug plan","author":"Baker","year":"2006"},{"issue":"1","key":"10.1016\/j.clml.2025.10.001_bib0051","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/hematology.2019000050","article-title":"Meeting the needs of CML patients in resource-poor countries","volume":"2019","author":"Malhotra","year":"2019","journal-title":"Hematology"},{"issue":"10","key":"10.1016\/j.clml.2025.10.001_bib0052","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/ajh.27445","article-title":"Optimal frontline therapy of chronic myeloid leukemia today, and related musings","volume":"99","author":"Kantarjian","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.10.001_bib0053","series-title":"Institute for Clinical and Economic Review","article-title":"Perspectives on cost-effectiveness thresholds in the United States","author":"McCabe","year":"2019"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.10.001_bib0054","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/JCO.2019.37.15_suppl.3060","article-title":"Is the optimal biological dose of oncologic molecular-targeted therapies also clinically effective?","volume":"37","author":"Corbaux","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.001_bib0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2019","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clml.2025.10.001_bib0056","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","article-title":"Low-dose dasatinib (50 mg Daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results","volume":"23","author":"Gener-Ricos","year":"2023","journal-title":"Clin Lymph Myelom Leukem"},{"issue":"11","key":"10.1016\/j.clml.2025.10.001_bib0057","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-dose dasatinib 50\u2009mg\/day versus standard-dose dasatinib 100\u2009mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.001_bib0058","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1182\/blood-2022-169777","article-title":"Low dose dasatinib is not As active in a CML CP cohort enriched with intermediate\/high-risk CML chronic phase: a phase IIb multi-center trial","volume":"140","author":"Abraham","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.001_bib0059","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2024-206740","article-title":"Response adapted Dasatinib de-escalation strategy compared to upfront low-dose Dasatinib: a prospective cohort study","volume":"144","author":"Singh","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.10.001_bib0060","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.001_bib0061","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2018-99-110543","article-title":"Efficacy and safety following dose reduction of Bosutinib or Imatinib in patients with newly diagnosed chronic myeloid leukemia: analysis of the phase 3 BFORE trial","volume":"132","author":"Brummendorf","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.001_bib0062","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.HS9.0000845676.81208.c2","article-title":"P698: bosutinib dose optimization in the second-line treatment of elderly cml patients: extended 3-year follow-up and final results of the best study","volume":"6","author":"Castagnetti","year":"2022","journal-title":"HemaSphere"},{"issue":"7","key":"10.1016\/j.clml.2025.10.001_bib0063","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.10.001_bib0064","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bjh.17286","article-title":"TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia","volume":"193","author":"Claudiani","year":"2020","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.10.001_bib0065","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2022-157822","article-title":"Three-year update from the optic trial: a dose-optimization study of 3 starting doses of Ponatinib","volume":"140","author":"Cortes","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.10.001_bib0066","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/ajh.26686","article-title":"Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia","volume":"97","author":"Kantarjian","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.001_bib0067","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.10.001_bib0068","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.clml.2025.10.001_bib0069","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.35384","article-title":"Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase","volume":"130","author":"Haddad","year":"2024","journal-title":"Cancer"},{"issue":"7647","key":"10.1016\/j.clml.2025.10.001_bib0070","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.clml.2025.10.001_bib0071","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jval.2020.11.010","article-title":"Budget impact of tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia with sustained deep molecular response","volume":"24","author":"Astrugue","year":"2021","journal-title":"Value in Health"},{"issue":"9","key":"10.1016\/j.clml.2025.10.001_bib0072","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.10.001_bib0073","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:48:43Z","timestamp":1773265723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042284"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia\u2014How to Define the Treatment Value?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}